Mon, April 22, 2013
Sun, April 21, 2013
Fri, April 19, 2013
Thu, April 18, 2013
Wed, April 17, 2013
Tue, April 16, 2013
Mon, April 15, 2013
Fri, April 12, 2013
Thu, April 11, 2013
[ Thu, Apr 11th 2013 ] - Market Wire
15 PM EDT
Wed, April 10, 2013
Tue, April 9, 2013
[ Tue, Apr 09th 2013 ] - Market Wire
30 a.m. ET
Mon, April 8, 2013
Sat, April 6, 2013
Fri, April 5, 2013
Thu, April 4, 2013
Wed, April 3, 2013
Tue, April 2, 2013
Mon, April 1, 2013
Fri, March 29, 2013
Thu, March 28, 2013
Wed, March 27, 2013
Tue, March 26, 2013
Mon, March 25, 2013
[ Mon, Mar 25th 2013 ] - Market Wire
Health Canada Decision Appealed
Sun, March 24, 2013
Fri, March 22, 2013

TPI Targets Qionglai Facility (QLF) Construction Completion in Mid April


//health-fitness.news-articles.net/content/2013/ .. ty-qlf-construction-completion-in-mid-april.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


TPI Targets Qionglai Facility (QLF) Construction Completion in Mid April -- CHENGDU, China, April 5, 2013 /PRNewswire/ --

CHENGDU, China, April 5, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: [ TPI ]), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today provided the progress update on its Qionglai Facility (QLF). After meeting several progress milestones, QLF construction is scheduled to be completed by April 15, 2013 which will be followed by GMP certification at the provincial level.

The pre-extraction facility will conduct initial processing of TCM raw material, separation using alcohol or water precipitation, filtration, centrifugation, concentration and purification of TCM pharmaceutical ingredients which will be further processed for the production of mTCM at the formulation facility.

About Pre-extraction and formulation plant development at QLF

In preparation for the new GMP standards stipulated by the PRC government in early 2011, TPI initiated the process of optimizing the manufacturing facilities in compliance with the new GMP standards. Due to the redesigning of the industrial parks in the suburbs of Chengdu, TPI's manufacturing facility at the Longquan district, east of Chengdu, is scheduled to be relocated to Qionglai city, south of Chengdu, which is designated for pharmaceutical industry. The QLF is approximately 18 miles from the Company's recently completed Jiangchuan macrolide (JCM) facility. The proposed relocation project also includes our TCM pre-extraction plant which is located near the center of Chengdu surrounded by rapidly expanding residential area. The QLF is estimated to be 80 mu or 53,000 square meters. The combined QLF plant, designed and constructed according to the latest GMP standards, is expected to relieve the current capacity saturation at TPI's facilities.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. For more information about TPI, please visit:  [ http://www.tianyinpharma.com ].

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: [ http://www.tianyinpharma.com ], or email [ ir@tpi.asia ]
Tel:     +86-28-8551-6696 (Chengdu, China)
          +86-134-3655-0011 (China)

Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza     
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China

SOURCE Tianyin Pharmaceutical Co., Inc.



RELATED LINKS
[ http://www.tianyinpharma.com ]

Publication Contributing Sources